Heart Failure

Five things for pharma marketers to know: Thursday, April 27, 2017

Five things for pharma marketers to know: Thursday, April 27, 2017

By

Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

By

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

By

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Novartis ups marketing investment in Entresto, by $200 million

Novartis ups marketing investment in Entresto, by $200 million

By

One oft-cited challenge to Entresto's adoption has been prior authorization requirements.

Practice Fusion founder launches heart-monitoring wearable

Practice Fusion founder launches heart-monitoring wearable

By

The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

By

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Five things for pharma marketers to know: Monday, September 14, 2015

Five things for pharma marketers to know: Monday, September 14, 2015

By

Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

By

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.